{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-050203","form_type":"8-K","ticker":"PALI","cik":"0001357459","company_name":"PALISADE BIO, INC.","filed_at":"2024-12-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.248124+00:00","generated_at":"2026-05-29T02:49:58.645812+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Palisade Bio Closes $5M Underwritten Public Offering of Units and Warrants","bullets":["Issued 158,000 Class A Units (common + warrant) and 3,120,688 Class B Units (prefunded warrant + warrant) at $1.525/$1.5249 per unit.","Gross proceeds $5 million; net proceeds approximately $4.1 million after underwriting discounts and expenses.","Proceeds to fund Phase 1 trial of PALI-2108, pre-clinical studies, R&D, and working capital.","Repriced approximately 1,040,217 previously issued warrants to $1.40 per share for participating investor.","Underwriter Ladenburg Thalmann & Co. Inc.; 45-day overallotment option for up to 491,803 additional shares/warrants."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-050203","json":"https://secwatch.observer/filing/0001493152-24-050203.json","markdown":"https://secwatch.observer/filing/0001493152-24-050203.md","text":"https://secwatch.observer/filing/0001493152-24-050203.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1357459/000149315224050203/0001493152-24-050203-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1357459/000149315224050203/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-29T02:49:58.645812+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}